Lord, Abbett & Co
TYRA icon

Lord, Abbett & Co’s Tyra Biosciences TYRA Stock Holding History

Lord, Abbett & Co’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.89M Buy
+121,833
New +$4.03M 0.01% 502

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Lord, Abbett & Co's TYRA Position: Q2 2026 in Review

Lord, Abbett & Co opened a new position in Tyra Biosciences (TYRA) in Q2 2026: 121,833 shares worth $3.89M. The stake represents 0.01% of the portfolio and ranks #502 among its holdings.

170 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Lord, Abbett & Co held 121,833 shares of Tyra Biosciences worth $3.89M as of Q2 2026.
  • Tyra Biosciences was a new Lord, Abbett & Co position in Q2 2026.
  • Tyra Biosciences made up 0.01% of Lord, Abbett & Co's portfolio in Q2 2026, its #502 holding.
  • 170 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.